In a big step for India’s weight loss drug market, Danish pharmaceutical company Novo Nordisk has officially launched Wegovy, its much-talked-about weight loss injection. The company is now competing directly with Eli Lilly’s popular drug, Mounjaro.
Wegovy is a once-a-week injection that comes in a pen-like device called FlexTouch. It's easy to use and doesn’t require vials or syringes. According to Managing Director of Novo Nordisk India, Vikrant Shrotriya, the drug will be available in pharmacies across India by the end of June 2025, The Times of India reported.
India’s obesity market is growing fast
India has one of the world’s highest numbers of people struggling with weight. Around 254 million people have general obesity and over 351 million suffer from belly fat-related issues. With the anti-obesity medicine market jumping from Rs 133 crore in 2021 to Rs 576 crore today (as per PharmaTrac), Novo Nordisk sees a huge opportunity.
Shrotriya said, “Obesity is a chronic illness and a growing problem in India. Wegovy is easy to use and will be priced specially for Indian patients.”
How Wegovy Works
Wegovy contains a compound called semaglutide, which mimics a natural hormone in the body. This hormone helps control blood sugar, reduce hunger, slow digestion, and make you feel full for longer. While similar drugs like Ozempic are meant for diabetes, Wegovy is approved for long-term weight loss.
It comes in a FlexTouch device, allowing users to adjust their weekly dose easily. Each monthly pack includes four needles. The medicine works on brain areas that manage appetite and food cravings.
According to Dr V. Mohan, a well-known diabetologist, “Semaglutide not only helps in weight loss but also improves heart and inflammation markers. It’s a strong option for Indian patients dealing with both obesity and rising heart risks.”
Wegovy India Price List
For comparison, Eli Lilly’s Mounjaro is slightly cheaper:
Almost like weight loss surgery, but with a catch
Wegovy has shown very strong results. In global studies, people lost up to 15% of their weight on average, and some even lost 20%. It also helped lower the risk of heart attacks and strokes and improved liver health.
However, the results are mostly maintained only if the person continues using the drug. If stopped, weight gain can return. Doctors also warn that muscle loss may happen over time, so people need to be regularly monitored.
Wegovy vs Mounjaro: What’s the Difference?
Inputs from TOI
Wegovy is a once-a-week injection that comes in a pen-like device called FlexTouch. It's easy to use and doesn’t require vials or syringes. According to Managing Director of Novo Nordisk India, Vikrant Shrotriya, the drug will be available in pharmacies across India by the end of June 2025, The Times of India reported.
India’s obesity market is growing fast
India has one of the world’s highest numbers of people struggling with weight. Around 254 million people have general obesity and over 351 million suffer from belly fat-related issues. With the anti-obesity medicine market jumping from Rs 133 crore in 2021 to Rs 576 crore today (as per PharmaTrac), Novo Nordisk sees a huge opportunity.
Shrotriya said, “Obesity is a chronic illness and a growing problem in India. Wegovy is easy to use and will be priced specially for Indian patients.”
How Wegovy Works
Wegovy contains a compound called semaglutide, which mimics a natural hormone in the body. This hormone helps control blood sugar, reduce hunger, slow digestion, and make you feel full for longer. While similar drugs like Ozempic are meant for diabetes, Wegovy is approved for long-term weight loss.
It comes in a FlexTouch device, allowing users to adjust their weekly dose easily. Each monthly pack includes four needles. The medicine works on brain areas that manage appetite and food cravings.
According to Dr V. Mohan, a well-known diabetologist, “Semaglutide not only helps in weight loss but also improves heart and inflammation markers. It’s a strong option for Indian patients dealing with both obesity and rising heart risks.”
Wegovy India Price List
For comparison, Eli Lilly’s Mounjaro is slightly cheaper:
Almost like weight loss surgery, but with a catch
Wegovy has shown very strong results. In global studies, people lost up to 15% of their weight on average, and some even lost 20%. It also helped lower the risk of heart attacks and strokes and improved liver health.
However, the results are mostly maintained only if the person continues using the drug. If stopped, weight gain can return. Doctors also warn that muscle loss may happen over time, so people need to be regularly monitored.
Wegovy vs Mounjaro: What’s the Difference?
Inputs from TOI
You may also like
India jumps to 3rd place in global tech startup funding in 1st half of 2025
“Ek taraf Mohammed, ek taraf Krishna”: Shubhman Gill's alleged 'Dono Tabahi' remark raised controversy
These sweets of Nepal are famous all over the world, they give tough competition to Indian sweets in taste
Rajnath Singh to head to China for key SCO defence talks; anti-terror focus tops agenda- first high-level visit since Ladakh standoff
Rajkummar Rao: Rajkumar Rao is nervous to play the role of Sourav Ganguly, said- 'This is a huge responsibility'..
